|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2003
Uptake of 18fluorodeoxyglucose in the cystic fibrosis lung: a measure of lung inflammation?
Depts of 1 Medicine and 2 Nuclear Medicine, McMaster University, ON, Canada
CORRESPONDENCE: M.B. Dolovich, Dept of Nuclear Medicine, McMaster University Medical Centre, 1V16, 1200 Main Street West, Hamilton, ON, L8N 3Z5, Canada. Fax: 1 9055461125. E-mail: mdolovic@mcmaster.ca
Keywords: cystic fibrosis, emission-computed, 18fluorodeoxyglucose, lung, neutrophils, tomography
Received: July 18, 2002
This study was funded by the Canadian Cystic Fibrosis Foundation (SPARX 2).
Positron emission tomography is a three-dimensional imaging technique that measures physiological effects, including metabolism. 18Fluorodeoxyglucose has been extensively used as a tracer of cellular energy metabolism in the brain and in tumour detection. As neutrophils utilise glucose as an energy source during their respiratory burst, it was hypothesised that 18fluorodeoxyglucose uptake, by these cells, could be interpreted as a measure of neutrophil activation in cystic fibrosis (CF).
Ten adult CF patients were given a bolus intravenous injection of 18fluorodeoxyglucose, followed by a 90-min dynamic mid-lung acquisition scan. Right-lung 18fluorodeoxyglucose uptake was assessed using a Patlak plot and values were converted to glucose utilisation. Three clinically inactive pulmonary sarcoidosis patients served as controls.
From the 10 CF patients with baseline sputum neutrophils of 14x106 cells·mL–1 who were investigated, seven were found to have sputum at a normal or slightly depressed glucose utilisation rate (mean 1.33 µmol·g–1·h–1) compared with a mean of 2.82 µmol·g–1·h–1 for the sarcoidosis patients. In eight patients, receiving inhaled tobramycin therapy, no change in lung glucose utilisation or sputum neutrophil counts were found.
Despite high-sputum neutrophil levels, lung glucose utilisation was not elevated in patients with cystic fibrosis.
This article has been cited by other articles:
|
|
 |
|
  M. Klein, M. Cohen-Cymberknoh, S. Armoni, D. Shoseyov, R. Chisin, M. Orevi, N. Freedman, and E. Kerem 18F-Fluorodeoxyglucose-PET/CT Imaging of Lungs in Patients With Cystic Fibrosis Chest, November 1, 2009; 136(5): 1220 - 1228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. R. Muzykantov Chair's Summary Proceedings of the ATS, August 15, 2009; 6(5): 398 - 402. [Full Text] [PDF]
|
|
|
|
|
|
M. B. Dolovich and D. P. Schuster Positron Emission Tomography and Computed Tomography versus Positron Emission Tomography Computed Tomography: Tools for Imaging the Lung Proceedings of the ATS, August 1, 2007; 4(4): 328 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Chen, T. W. Ferkol, M. A. Mintun, J. E. Pittman, D. B. Rosenbluth, and D. P. Schuster Quantifying Pulmonary Inflammation in Cystic Fibrosis with Positron Emission Tomography Am. J. Respir. Crit. Care Med., June 15, 2006; 173(12): 1363 - 1369. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. Jones Inflammation Imaging Proceedings of the ATS, December 1, 2005; 2(6): 545 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. de Jong, N. L. Muller, P. D. Pare, and H. O. Coxson Computed tomographic imaging of the airways: relationship to structure and function Eur. Respir. J., July 1, 2005; 26(1): 140 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Dolovich and R. Labiris Imaging Drug Delivery and Drug Responses in the Lung Proceedings of the ATS, December 1, 2004; 1(4): 329 - 337. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |